Visualase

Visualase develops, manufactures, and sells minimally invasive laser ablation systems and their related disposables, for the purpose of destroying tumors and other soft tissue. The Visualase technology is proprietary, IP protected, and game changing. The Visualase system is fully developed, FDA cleared with a broad indication, and is currently being used commercially in the US. Visualase, because of the unprecedented level of control and precision offered by the technology, faces several large patient populations who have no options, in markets that have never been accessed by previous ablative technologies.

Visualase has begun treating patients both ‘on protocol’ and ‘off protocol’ in a commercial setting, for a variety of applications at MD Anderson, Mayo Clinic, Cleveland Clinic, UCSF, North Shore Hospital (Long Island), Rhode Island Hospital (Brown University Medical College), and Willis Knighton Medical Center (Shreveport).

The Visualase system is comprised of three components:

1) a 980 nm diode laser generator that produces the light energy used for the ablation,

2) a proprietary diffusing laser ablation probe with cooling catheter to deliver the energy to the desired target, and quickly throughout the entire the ‘kill zone’

3) workstation that allows visualization, control, and monitoring of the ablation in real time, as well as modeling of the of the kill zone while it is being created.

The sharp demarcation of dead vs. unharmed tissue (<1mm) associated with the energy source, combined with the ability to monitor and control the ablation while modeling the kill zone in real time to sub-millimeter levels of accuracy, offers a level of precision never before attained in previous ablative therapies. Visualase is actively pursuing applications in brain, spine, and prostate. The technology also lends itself favorably (and is being pursued by physicians at institutions such as Cleveland Clinic and Mayo Clinic) for liver and kidney tumors, as well as tumors of the thyroid, breast, and bone, and even for epilepsy applications. The Visualase system is truly a platform technology.